Beaufort T M, Nigrovic V, Proost J H, Houwertjes M C, Wierda J M
Research Group for Experimental Anesthesiology and Clinical Pharmacology, University of Groningen, The Netherlands.
Anesthesiology. 1998 Sep;89(3):707-14. doi: 10.1097/00000542-199809000-00022.
The factors that influence the onset time of submaximal (<100%) neuromuscular block are not fully known. The authors hypothesized that differences in the rate of decrease in the plasma concentration result in differences in the rate of equilibration between plasma and biophase and thus in different onset times. If this hypothesis is valid, inhibition of the enzymic degradation of muscle relaxants should increase the onset time of neuromuscular block.
Twenty pigs received either suxamethonium or mivacurium. Dose finding (70% block) was done for each pig. The enzymic degradation of the muscle relaxant was randomly inhibited by selective inhibition of plasma cholinesterase activity by tetraisopropyl pyrophosphoramide (10 pigs) or was not inhibited (10 pigs). Plasma cholinesterase activities and the mechanomyographic muscle response after peroneal nerve stimulation (0.1 Hz) were measured.
Inhibition of plasma cholinesterase activity (by 93% and 89%, respectively) increased the onset time of suxamethonium from a median of 40 s (range, 20-45 s) to 131 s (range, 114-166 s; P = 0.009) and of mivacurium from a median of 52 s (range, 40-59 s) to 105 s (range, 90-125 s; P = 0.009). Inhibition of degradation decreased the effective dose of suxamethonium that resulted in 70% depression of the initial twitch height from 900 microg/kg (range, 400-1,000 microg/kg) to 150 microg/kg (range, 135-150 microg/kg) and of mivacurium from 100 microg/kg (range, 80-150 microg/kg) to 35 microg/kg (range, 20-50 microg/kg).
Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block. Therefore, pharmacokinetics influence the onset time of submaximal neuromuscular block. These results imply that to obtain an ultrashort onset time, muscle relaxants should be developed that not only have a low affinity for the receptor but also rapidly disappear from plasma.
影响次最大(<100%)神经肌肉阻滞起效时间的因素尚未完全明确。作者推测,血浆浓度下降速率的差异导致血浆与生物相之间平衡速率的差异,进而导致起效时间不同。如果这一假设成立,抑制肌肉松弛剂的酶促降解应会延长神经肌肉阻滞的起效时间。
20头猪分别接受琥珀胆碱或米库氯铵。对每头猪进行剂量探索(达到70%阻滞)。通过四异丙基焦磷酰胺选择性抑制血浆胆碱酯酶活性,随机抑制10头猪肌肉松弛剂的酶促降解,另外10头猪不进行抑制。测量血浆胆碱酯酶活性以及腓总神经刺激(0.1Hz)后的肌机械图肌肉反应。
抑制血浆胆碱酯酶活性(分别抑制93%和89%)使琥珀胆碱的起效时间从中位数40秒(范围20 - 45秒)延长至131秒(范围114 - 166秒;P = 0.009),米库氯铵的起效时间从中位数52秒(范围40 - 59秒)延长至105秒(范围90 - 125秒;P = 0.009)。降解抑制使导致初始颤搐高度降低70%的琥珀胆碱有效剂量从900μg/kg(范围400 - 1000μg/kg)降至150μg/kg(范围135 - 150μg/kg),米库氯铵的有效剂量从100μg/kg(范围80 - 150μg/kg)降至35μg/kg(范围20 - 50μg/kg)。
抑制琥珀胆碱和米库氯铵的酶促降解会延长次最大神经肌肉阻滞的起效时间。因此,药代动力学影响次最大神经肌肉阻滞的起效时间。这些结果表明为获得超短起效时间,应研发不仅对受体亲和力低而且能迅速从血浆中消失的肌肉松弛剂。